Bruno Montanari
Partner @ Omnes Capital
Paris, France
Bruno Montanari is a Series A investor at Omnes Capital in Paris focused on Health Care and Biotechnology. Bruno Montanari began his career in 1999 working in investment banking in London at Deutsche Bank, then Merrill Lynch, before moving into venture capital, initially at CDP Capital, then at Atlas Venture. He joined Omnes Capital in 2010.Bruno currently sits on the board of directors of several companies (including Horama, Novate, Themis) andpreviously served on the boards of various companies such as arGEN-X (Euronext Brussels: ARGX), EOS imaging (Euronext Paris: EOSI), Poxel (Euronext Paris: POXEL). Bruno graduated with a master’s degree in Strategic Management from the HEC business school and holds a PharmD (University Paris V).
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Bruno Montanari invests in
Stages Bruno Montanari invests in
Countries Bruno Montanari invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (80%)
- Biotechnology 4 (80%)
- Medical 3 (60%)
- Medical Device 2 (40%)
- Hospital 1 (20%)
Stage
- Series A 3 (60%)
- Series B 1 (20%)
Country
- Italy 1 (20%)
- France 1 (20%)
- Ireland 1 (20%)
- United Kingdom 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. | $23M / Series A / Oct 04, 2022 | ||
| Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $17.8M / Series A / May 20, 2019 | ||
| TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | $25.5M / Series A / Mar 17, 2016 | ||
| TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | $8.8M / Series A / Dec 09, 2013 | ||
| NOvate Medical Technologies is a New Orleans-based medical device development company, focused on commercializing high-quality, low-cost, and sustainable medical products while addressing critical global health needs. NOvate’s first product offering, InfaClip, previously known as SafeSnip, is a patented disposable plastic obstetric device thatsimultaneously cuts, clamps, and shields the infant, mother, and birthing attendant from infection, aimed at reducing maternal and neonatal mortality in developing countries. | $9.9M / Series B / May 21, 2011 |
Co-Investors
About Omnes Capital
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Omnes Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fabien Collangettes
Partner
|
|||
Fabien Prevost
CEO
|
|||
Laurent Perret
Principal & Director of investments
|
|||
Michael Pollan
Investment Director, Renewable Energy
|
|||
Pierre-Axel Botuha
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bruno Montanari invest in?
Bruno Montanari invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bruno Montanari?
Public channels for Bruno Montanari include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bruno Montanari last invest?
The most recent investment recorded for Bruno Montanari closed in Oct 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
